Post-Market Surveillance for Overseas Registration of Rehabilitation Devices: How to Implement It?

Rehabilitation device manufacturers must conduct ongoing post-market surveillance (PMS) after overseas registration, as this is a legal obligation to maintain the validity of the registration certificate. Start by confirming product classification and post-registration requirements under the target country's regulations, then establish a systematic surveillance plan covering adverse event reporting, risk management updates, clinical evaluation maintenance, and label/instructions for use management. In markets such as Europe, the United States, and GHWP member states, technical documentation and quality system evidence generated during initial registration with NMPA, CE, or FDA can be reused, but must be localized to the local language, regulations, and patient populations.

Key Summary

After overseas registration, manufacturers must continuously perform post-market surveillance to keep the registration certificate valid. This includes establishing a systematic surveillance plan that addresses adverse event reporting, risk management updates, clinical evaluation maintenance, and label management. For markets such as the EU, US, and GHWP member states, existing technical documentation from NMPA, CE, FDA, or ISO 13485 can be leveraged, but localization is essential. Common risks include improper change management, delayed adverse event reporting, unclear responsibilities of the local representative, and outdated clinical data. Manufacturers should designate a dedicated PMS officer, collaborate closely with authorized representatives, collect real-world data, and conduct periodic risk assessments to ensure product safety and continued certificate validity.

Applicable Scenarios and Core Issues

Rehabilitation devices that have completed overseas registration are not at the end of the regulatory process; rather, they enter a phase of continuous compliance obligations. The question is not whether to conduct surveillance, but how to systematically establish and execute a surveillance plan with existing resources, and then use the results to maintain certificates and expand market access.

Applicable scenarios include: products already on the market in a country that require continued maintenance of the registration certificate; manufacturers planning to expand the same device to multiple GHWP member states; or situations where changes are needed due to regulatory updates, clinical feedback, or supplier changes. Core issues include collecting not only adverse events but also product tracking, user satisfaction, clinical follow-up, literature reviews, and periodic re-evaluation of the risk-benefit profile. Manufacturers must clarify responsibility boundaries: which tasks fall to the local agent, which to the headquarters PMS team, and which can be outsourced to a CRO. For cross-border sales, time zone and language differences must not delay reporting; a 24-hour channel for receiving serious adverse event information is essential.

Registration Decision Logic

First, determine the regulatory scope and risk classification. Not all rehabilitation devices are high-risk; manual wheelchairs may be Class I low-risk, while rehabilitation robots and implantable neurostimulators may be high-risk. Check the classification rules of the target country. Under the EU MDR, classification determines the conformity assessment route and the intensity of PMS. In the US FDA, classification and product code determine whether a 510(k) or PMA is required. In GHWP member states, there may be localized classification differences.

Second, confirm the registration path. Low-risk products often use self-declaration or simplified registration, but periodic safety updates are still required. Medium- and high-risk products require certification body involvement and audit of the PMS plan. Also confirm the applicant entity: local legal entity or foreign manufacturer? Many countries require a local authorized representative who is responsible for communicating with regulators, receiving adverse event reports, and assisting with product withdrawals. Failure to designate a qualified and stable agent can lead to revocation of the registration certificate and mandatory product recall.

Third, assess the reuse of existing documentation. If the product already has NMPA registration, CE certification, or FDA clearance, the associated risk management, clinical evaluation, ISO 13485 system, or MDSAP certificates can serve as a basis. However, each country has different formats and language requirements for post-market data. Conduct a gap analysis to determine which documents can be reused after translation and which must be generated from local data. For example, some European countries require PSURs in the local language, while Thailand may require local safety monitoring data or enhanced complaint handling records.

Fourth, confirm the specific post-market obligations. This includes adverse event reporting timelines, annual updates or Periodic Safety Update Reports (PSURs), whether labels and instructions need updating after product changes, local language requirements, and local clinical data requirements. Some GHWP member states require registration holders to submit sales data and adverse event summaries for the past several years at the time of renewal; these data must be readily retrievable from internal systems.

Materials and Evidence

A complete documentation system is required for post-market surveillance. The risk management file must be dynamically updated to incorporate newly identified risks and the effectiveness of risk control measures. The clinical evaluation report should be updated if new literature or adverse event trends emerge. In the quality system, corrective and preventive actions (CAPA), complaint handling, and return records are also regulatory focus areas.

Typical documentation for rehabilitation devices includes: technical documentation, declaration of conformity, labels and instructions for use and their change records, design change records, component supplier change records, software update records (if applicable), unique device identifier (UDI) files for traceability, and the PMS plan itself. Devices with electrical components must also track updates to electromagnetic compatibility and electrical safety standards, which often require retesting and new reports.

Traceability and evidence chains are critical. Maintain records of the rationale and validation for each change, communications with the local agent, responses to regulatory inquiries, and submission confirmations for adverse event reports. Many GHWP member states require patient information in English or the local language, so bilingual versions should be prepared. All records should be retained for at least 10 years, or longer if required by local regulations.

Data sources for PMS can be proactive (e.g., periodic follow-up visits, user surveys, clinical data registries) or passive (e.g., complaints, adverse events, literature searches, competitor safety information). Establish systems to collect, analyze, and regularly review this data. If the product includes software, monitor cybersecurity vulnerabilities and maintain evidence of regression testing after updates. For rehabilitation devices using mobile apps or remote monitoring, also consider data privacy regulations that may limit post-market data collection.

Common Mistakes

• Treating post-market surveillance as merely adverse event reporting, only activating the process when serious events occur.
• Ignoring the relationship between product changes and registration certificate changes; changing components or software versions without assessing the need to update the registration.
• Directly reusing CE or FDA technical documentation without localizing for local regulations and language, leading to application rejection or deficiencies during post-market inspections.
• Lacking information synchronization with the local agent, preventing timely responses to regulatory inquiries or report submissions.
• Failing to establish effective complaint and feedback channels, so user issues never enter the quality management system.
• Leaving clinical evaluation and risk management documents outdated, disconnected from actual product use and the latest scientific evidence.
• Not including PMS data in management reviews, leaving senior management unaware of the product's true safety performance.

Company Preparation Checklist

• Develop and update a written PMS plan that clearly defines responsibilities, processes, frequencies, and data sources.
• Establish internal procedures for adverse event reporting and vigilance data comparison, and conduct periodic mock drills.
• Designate a PMS officer for global and country-specific responsibilities, and clarify collaboration mechanisms with local agents.
• Maintain and dynamically update risk management files and clinical evaluation reports, retaining evidence for all changes.
• Establish label and instructions for use control procedures to ensure consistency with the latest registration information, and prepare local-language versions.
• Perform regular regulatory gap analyses and track changes in target market regulations, adjusting registration certificates and documentation accordingly.
• Sign clear agreements with local authorized representatives specifying responsibilities for surveillance, reporting, and product withdrawal.
• Implement an annual review mechanism to verify the effectiveness of the PMS plan and produce a management review report.

AIMEILI View: Regulatory Interpretation and Business Impact

From our experience as a regulatory consultancy, the most common misjudgment is assuming that once a registration certificate is obtained, it remains valid indefinitely. In reality, the value of the certificate depends on the manufacturer's continuing ability to demonstrate product safety and effectiveness. Regulatory updates, clinical feedback, and even recalls of competing products can affect an existing registration. Therefore, post-market surveillance is not a cost but the most important means of protecting your registration investment.

In the early stages of a project, we recommend conducting a regulatory status inventory: list all PMS requirements for the target market in a table, including reporting deadlines, language, templates, and responsible parties; then assess existing internal data to determine what can be reused and what needs to be supplemented. This avoids costly rework later. Do not wait until after product launch to prepare; allocate PMS resources during the registration phase.

Regarding documentation, ISO 13485 system files and risk management reports can generally be reused across countries, but clinical evaluation, labels, instructions for use, and patient education materials must be localized. For rehabilitation devices, patient use instructions, warnings, and cultural semantic differences affect safety and cannot be translated mechanically. We have encountered cases where improper label translation led to patient use errors and subsequent regulatory penalties.

The local agent is not a mere contact person; they carry legal obligations and serve as the trust bridge between the manufacturer and regulators. Maintain control of the registration certificate to avoid invalidation due to agent non-payment or departure. Plan for changes and renewals well in advance; change applications are often more complex than initial registrations, and renewals require proof of continued sales and post-market data. Agent contracts should include clear service periods, data access rights, and domain ownership clauses to protect against acquisition or market exit.

For multi-country registrations, we recommend building a core document library that transforms technical documentation, clinical evidence, and risk analysis into reusable modules, then localizes the packaging for each country. This significantly reduces duplicate work and correction risk. GHWP member states accept regional data but have different submission formats; professional project management avoids the need to redraft the same data three times. If you plan to register successively in multiple countries, involving the same consultancy team can help unify standards and improve efficiency.

Common Follow-up Questions

What periodic reports must be submitted to regulators after overseas registration of rehabilitation devices?

It depends on the target market. The EU MDR requires Periodic Safety Update Reports (PSURs) for Class IIa and above devices, while the US FDA typically requires annual reports describing product changes and post-market data. GHWP member states such as Saudi Arabia and Thailand also have their own requirements, often as annual reports or data packages submitted during registration renewal. Manufacturers should proactively confirm the next reporting deadline after registration and establish data collection templates in advance to avoid last-minute collection that compromises report quality.

If a minor malfunction occurs that causes no harm, is it mandatory to report?

Many countries have clear reporting timelines for serious adverse events, but minor malfunctions are not always reportable. However, a minor malfunction may be a risk signal. Manufacturers should record, assess, and track it within their quality system. If the same malfunction recurs, the risk level may escalate, and you must update the risk analysis and consider whether a supplementary report is needed. For rehabilitation devices, if a malfunction prevents device use and affects patient rehabilitation progress, it should be carefully evaluated.

If expanding from Europe to GHWP member states, can existing CE clinical data be used directly for local post-market surveillance?

Partial reuse is possible, but local regulatory and clinical practice differences must be considered. CE clinical data can serve as a foundation, but GHWP member states may require additional local clinical data or updated literature, especially for rehabilitation devices where patient populations, usage environments, and demographics can affect safety and effectiveness. Conduct a gap analysis and supplement with local-language patient follow-up data. Also incorporate any special local weather or usage conditions into the risk management scope.

Related Articles

• When Should Change Registration Be Filed for Overseas Registration of Rehabilitation Devices?
• What Should Be Prepared Before Renewal of Overseas Registration for Rehabilitation Devices?
• What to Do When Quality System Certificates Are Inconsistent for Rehabilitation Device Registration?
• How to Determine Product Classification for Overseas Registration of Implantable Products?
• How to Organize Technical Documentation for Overseas Registration of Implantable Products?
• How Are Authorized Representative Responsibilities Divided for Imaging Device Overseas Registration?

Content Review and Applicability

Content author: AIMEILI Regulatory Editorial Department. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: Priority is given to official regulatory agencies, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as auxiliary references. Applicability: This article is intended for preliminary understanding, document preparation, and project planning. It does not replace the official requirements of the target country's regulatory authority, testing conclusions, or legal advice.

Published: 2026-08-17 14:42 | Updated: 2026-08-17 14:42